Orrie Friedman was one of the pioneers of biotechnology, but at 92 it's still way too early to start talking retirement. He's now betting that his company, Grand Pharma, can generate some excitement around the notion that silica-based compounds can dissolve amyloid plaques, which are associated with Alzheimer's. He's also betting that a new paper on their work will grab the attention of a deep-pocketed pharma company and that a successful development program will create a billion-dollar windfall. Oh, and he wants to give most of that money away.
- read the report [1] from The Boston Globe
Related Articles:
Big pharma sees big payback for Alzheimer's research. Report [2]
Enzyme essential to preventing Alzheimer's. Report [3]
Gene combo dramatically increases risk of Alzheimer's. Report [4]
Links:
[1] http://www.boston.com/news/science/articles/2007/07/23/he_wants_to_use_biotech_against_alzheimers/
[2] http://www.fiercebioresearcher.com/story/big-pharma-sees-big-payback-for-alzheimer-s-research/2007-06-12
[3] http://www.fiercebioresearcher.com/story/enzyme-essential-to-preventing-alzheimer-s/2006-10-26
[4] http://www.fiercebioresearcher.com/story/gene-combo-dramatically-increases-risk-of-alzheimer-s/2007-06-12